DNTH Dianthus Therapeutics, Inc. /DE/
FY2025 10-K
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its fiscal year 2025 10-K annual report with the SEC on Mar 9, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development of claseprubart and DNTH212 biopharmaceutical candidates reliant on outsourced manufacturing and clinical trial services
- • New emphasis: Impact of the BIOSECURE Act (Dec 2025) restricting collaborations with certain Chinese biotech firms, including sole manufacturer WuXi Biologics
Management Discussion & Analysis
- • No revenue reported, no year-over-year change disclosed
- • Net loss reported; specific profitability or margin figures not provided
Risk Factors
- • Regulatory risk: Dependence on FDA approval for claseprubart and DNTH212 with uncertain timing and outcomes for clinical trial phases and marketing approvals
- • Geopolitical risk: License and development agreements with Tenacia Biotechnology for Greater China involving clinical trial cost sharing and milestone payments up to $15 million
Financial SummaryXBRL
Revenue
$2M
Net Income
-$162M
Operating Margin
-8739.3%
Net Margin
-7973.3%
ROE
-32.9%
Total Assets
$531M
EPS (Diluted)
$-4.20
Operating Cash Flow
-$129M
Source: XBRL data from Dianthus Therapeutics, Inc. /DE/ FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Dianthus Therapeutics, Inc. /DE/
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.